"The creativity, drive and collaborative spirit I share with my colleagues inspire and motivate me to strive for innovation in drug discovery."
I joined Genentech in 2008 as a Scientist in Translational Oncology, and my laboratory has carried out research on several areas of Oncology including Cancer Signaling, Tumor Metabolism and Cancer Immunology. I am currently a Senior Scientist in Translational Oncology and my current research aims to understand the mechanisms of regulation of the PI3K pathway that is the most frequently altered pathway in cancer.
What attracted me to Genentech was the potential to do cutting-edge research with a direct impact on cancer patients' lives. Since joining, I have had the opportunity to work with colleagues across the organization on exciting projects and have drawn inspiration from the creativity and drive that is an integral part of the research culture here. My current area of research aims to identify novel players involved in the regulation of PI3K activity with the goal of discovering new ways to target this critical pathway.
J Biol Chem. 2017 Sep 1;292(35):14311-14324.
Nature. 2013 Sep 12;501(7466):232-6.
My laboratory focuses on the discovery and validation of new therapeutic targets in oncology. Our current area of investigation is the PI3K pathway and specifically the mechanisms of regulation of PI3K signaling with the goal of identifying novel strategies for therapeutic targeting of this pathway. We use biochemical, cell and molecular and proteomic approaches and perform structure/function studies as well as genetic screens to characterize the wiring and regulation of mutant PI3K signaling pathways in breast and colorectal cancer.
Previous work from my laboratory has focused on deciphering the regulation and targeting of the RAF/MAPK pathway in cancer, characterizing the role of tumor metabolism pathways in tumorigenesis and investigating therapeutic strategies for reversing tumor immune suppression and boosting anti-tumor immune responses.